REGULATORY
PMDA’s Science Committee Holds 1st Meeting; Will Work to Improve Review Quality through Exchanges with Researchers
The Pharmaceuticals and Medical Devices Agency’s (PMDA) Science Committee (chairman: Prof. Tatsuro Irimura, the University of Tokyo Graduate School of Pharmaceutical Sciences), which was recently established as a forum for discussions with university and other researchers on leading-edge technologies including…
To read the full story
REGULATORY
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
- LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





